Embecta

Embecta R&D Expenses

The Research & Development Expenses of Embecta (EMBC) as of Nov 11, 2026 is 21.50 M USD. In the previous year, Research & Development Expenses was 78.80 M USD — a change of -72.72% (lower).

R&D Expenses

21.50 MUSD

YoY

-72.72%

Last updated:

Research & Development Expenses of Embecta is 2025 21.50 M USD. Research & Development Expenses of Embecta was 2024 78.80 M USD. It decreases by -72.72% lower compared to the previous year.

The Embecta R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2019
62.00 M USD
Jan 1, 2020
61.00 M USD
Jan 1, 2021
63.00 M USD
Jan 1, 2022
65.00 M USD
Jan 1, 2023
85.20 M USD
Jan 1, 2024
78.80 M USD
Jan 1, 2025
21.50 M USD
The Embecta R&D Expenses history
YEARR&D ExpensesYoY
21.50 MUSD-72.72%
78.80 MUSD-7.51%
85.20 MUSD+31.08%
65.00 MUSD+3.17%
63.00 MUSD+3.28%
61.00 MUSD-1.61%
62.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Research & Development Expenses of Embecta is 21.50 M USD in 2025.

Research & Development Expenses of Embecta changed from 78.80 M USD to 21.50 M USD, representing a -72.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Embecta since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Embecta

All Key Metrics — Embecta